Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

523
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.4K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.4K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.6K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

347
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circumstances and triggering factors for major arrhythmic events in Brugada Syndrome patients without spontaneous type 1 ST elevation.

Heart rhythm·2026
Same author

Clinical Impact of Guideline-Directed Medical Therapy in Patients with Left Ventricular Assist Device: An International Multicenter Study.

ESC heart failure·2026
Same author

Duration of heart failure as a determinant of outcomes after left ventricular assist device implantation: an international multicenter study.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Clinical Impact and Prediction of Early Electrical Storm in Patients With Left Ventricular Assist Device.

JACC. Clinical electrophysiology·2026
Same author

Impact and safety of remote monitoring of heart failure patients managed with the HeartLogic algorithm: the HeartLogic France Cohort Study.

European heart journal. Digital health·2026
Same author

Pulmonary vein isolation alone vs adjunctive ablation for first persistent atrial fibrillation: A real-world target-trial emulation.

Heart rhythm·2026
Same journal

The Importance of Atrial Fibrillation's Associated Comorbidities as Clinical Presentation and Outcome Contributors.

Journal of atrial fibrillation·2021
Same journal

The story of a Migrating Pericardial Drain and Perforation!

Journal of atrial fibrillation·2021
Same journal

Incidence of New Onset Atrial Fibrillation After Cardiovascular Surgery in Vietnam: Results From A Novel Screening Strategy.

Journal of atrial fibrillation·2021
Same journal

Effect of SLGT2 Inhibitors on Patients with Atrial Fibrillation.

Journal of atrial fibrillation·2021
Same journal

Same Day versus Overnight Discharge in Patients Undergoing Ablation for Atrial Fibrillation (SODA) Study.

Journal of atrial fibrillation·2021
Same journal

Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology Of Atrial Fibrillation.

Journal of atrial fibrillation·2021
See all related articles

Related Experiment Video

Updated: Mar 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Statin and Atrial Fibrilation: When does it work?

Laurent Fauchier1, Nicolas Clementy1, Bertrand Pierre1

  • 1Service de Cardiologie B, Pôle Cœur Thorax Vasculaire, Centre Hospitalier Universitaire Trousseau, Tours, France Faculté de Médecine Université François Rabelais, Tours, France.

Journal of Atrial Fibrillation
|May 13, 2017
PubMed
Summary
This summary is machine-generated.

Statins show mixed results for preventing atrial fibrillation (AF). While they reduce post-operative AF risk, their benefit in primary prevention and secondary prevention of AF is less clear and varies among patients.

Keywords:
Atrial Fibrillationinflammationprimary preventionsecondary preventionstatin.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Mar 2, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Emerging evidence suggests statins may offer protection against atrial fibrillation (AF).
  • The anti-inflammatory and antioxidant properties of statins are hypothesized mechanisms for AF prevention.
  • Inflammation is a known factor in the development of AF.

Purpose of the Study:

  • To analyze the association between statin use and the risk of atrial fibrillation (AF) incidence and recurrence.
  • To evaluate the efficacy of statins in different clinical scenarios of AF prevention and management.
  • To determine the role of statins in patients with and without established atherosclerotic disease.

Main Methods:

  • Global literature analysis of clinical and experimental studies.
  • Review of data on primary prevention, secondary prevention, and post-operative AF.
  • Assessment of the impact of intensive lipid-lowering statin regimens.

Main Results:

  • Statin use is associated with a decreased risk of AF incidence and recurrence in some cases.
  • No clear benefit of statins in the primary prevention of AF.
  • Significant but heterogeneous risk reduction for AF recurrence in secondary prevention.
  • A significant and homogeneous reduction in the risk of post-operative AF.
  • Intensive statin therapy does not enhance AF protection.
  • Potential benefit in AF patients without atherosclerotic disease requires further investigation.

Conclusions:

  • Statin therapy demonstrates a clear benefit in reducing post-operative AF.
  • The role of statins in primary and secondary AF prevention is complex and patient-dependent.
  • Current evidence does not support prescribing statins solely for AF prevention in patients without atherosclerotic disease.